Education
About Us
Working with TipRanks
Follow Us
CryoPort Inc (CYRX)
NASDAQ:CYRX
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.27Last Year’s EPS
-1.62Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 23.67%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook for Cryoport, with significant revenue growth, strategic partnerships, and strong performance in its Life Sciences Services segment. While there were concerns about tariffs and contingent considerations, these were outweighed by the company's achievements and growth forecasts.Company Guidance
During Cryoport's First Quarter 2025 Earnings Call, the company provided guidance for fiscal year 2025, projecting revenue in the range of $165 million to $172 million, which represents a 7.5% growth at the midpoint compared to fiscal year 2024. The first quarter saw $41 million in revenue from continuing operations, marking a 10% year-over-year increase, driven notably by a 17% growth in Life Sciences Services revenue. This growth included a substantial 33% rise in support for commercial cell and gene therapies. Life Sciences Services now constitute 56% of Cryoport's total revenue. The company also highlighted its strategic partnership with DHL, which is expected to enhance Cryoport's competitive position, particularly in Asia Pacific and EMEA regions, following the sale of CryoPDP to DHL for $195 million. Additionally, Cryoport is confident in its organic growth outlook and aims to return to positive adjusted EBITDA during 2025, despite potential impacts from global tariffs, which they plan to mitigate through supply chain diversification and surcharges.Revenue Growth and Strategic Partnership
Cryoport reported $41 million in revenue from continuing operations for the first quarter, representing a 10% year-over-year growth. The strategic partnership with DHL was announced, involving the sale of CryoPDP to DHL for an enterprise value of $195 million.
Life Sciences Services Performance
Life Sciences Services revenue increased 17% year-over-year. The segment supported 19 commercial therapies and 711 clinical trials, representing approximately 70% of cell and gene therapy trials. Commercial cell and gene therapies grew 33% over the previous year.
Product Launches and Market Expansion
Cryoport launched the MVE High Efficiency 800C and noted demand stabilization in its Life Sciences Products business, which grew 2% year-over-year.
Positive Outlook and Guidance
Cryoport confirmed its revenue guidance for fiscal year 2025 in the range of $165 million to $172 million, representing a 7.5% growth relative to fiscal year 2024.
CYRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $5.66 | $6.98 | +23.32% |
Mar 04, 2025 | $5.06 | $6.61 | +30.63% |
Nov 07, 2024 | $8.02 | $7.73 | -3.62% |
Aug 06, 2024 | $7.79 | $7.77 | -0.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CryoPort Inc (CYRX) report earnings?
CryoPort Inc (CYRX) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is CryoPort Inc (CYRX) earnings time?
CryoPort Inc (CYRX) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYRX EPS forecast?
CYRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.27.